Development of novel topical tranexamic acid liposome formulations.
The aims of this study were to develop novel liposome formulations for tranexamic acid (TA) from various lipid compositions [neutral (hydrogenated soya phosphatidylcholine and cholesterol), positive (stearylamine) or negative (dicetyl phosphate) charged lipid], and to investigate the effects of concentrations of TA (5 and 10% in DI water) and charges on the physicochemical properties of liposomes. Liposomes were prepared by chloroform film method with sonication. The physical (appearance, pH, size, morphology) and chemical (drug encapsulation efficiency, transition temperature, enthalpy of transition) properties of liposomes were characterized. The TA contents were determined spectrophotometrically at 415 nm, following derivatization with 2,4,6-trinitrobenzosulfonic acid. The charged liposomes demonstrated better physical stability than the neutral liposomes. The percentages of TA entrapped in all liposome formulations varied between 13.2 and 15.6%, and were independent of TA concentrations and charges of liposomes. Charges affected the physical stability, pH and size of liposomes. The particle sizes of negative blank and positive liposomes (with and without the entrapped drug) were approximately 10 times larger than the negative liposome with the entrapped TA. The multilamellar 7:2:1 molar ratio of hydrogenated soy phosphatidylcholine/cholesterol/dicetyl phosphate entrapped with 10% TA liposome (10%TA,-) was selected for further release study, due to its high physical stability, small particle size and relatively high drug encapsulation efficiency.
Manosroi
A
A
Institute for Science and Technology Research and Development, Pharmaceutical-Cosmetic Raw Materials and Natural Products Research and Development Center, Faculty of Pharmacy, Chiang Mai University, 50200, Chiang Mai, Thailand. pmpti005@chiangmai.ac.th
Podjanasoonthon
K
K
Manosroi
J
J
D000287:Administration, Topical; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006863:Hydrogen-Ion Concentration; D008081:Liposomes; D010316:Particle Size; D013678:Technology, Pharmaceutical / Q000379:methods*; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000737:chemistry*
D000933:Antifibrinolytic Agents; D008081:Liposomes; D014148:Tranexamic Acid